Phase 3 Win for TED Therapy - Summary - MDSpire
Clinical Guidelines
Feature

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

  • May 8, 2026

  • 3 min

Share

Amgen's phase 3 trial of a subcutaneous formulation of teprotumumab (TEPEZZA) for moderate-to-severe active thyroid eye disease (TED) showed promising results. 77% of participants achieved proptosis response at 24 weeks, significantly higher than the 19.6% in the placebo group. The subcutaneous version aims to provide comparable efficacy with improved convenience via an on-body injector every two weeks. Findings suggest potential benefits in overall responder rates and quality of life, with safety profiles aligned with the intravenous form. Full results will be shared at a medical congress, marking a promising development for TED treatment.

Original Source(s)

Phase 3 Win for TED Therapy

  • May 8, 2026

Related Content

Retinal Ischemia as Stroke Warning

Retrospective study investigates links between acute ischemic ocular events and increased stroke risk

  • May 8, 2026

  • 3 min
Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Chatbots Enter Retinal Care

New research shows how conversational AI might improve patient understanding and engagement in retinal detachment pathways

  • May 7, 2026

  • 3 min